Lettmann Jason 4

What Happened

• Jason Lettmann, CEO of ALX Oncology Holdings Inc. (ALXO), was granted a derivative award covering 912,000 shares on 2026-01-26. The filing lists a per-share amount of $0.00 for the award; total dollar value is not reported in the excerpt. This is a grant/award (not a cash purchase or sale).

Key Details

• Transaction date: 2026-01-26; SEC filing date: 2026-01-28 (timely under the Form 4 two-business-day rule).
• Transaction type/code: Grant/Award (derivative), reported as “A.”
• Shares involved: 912,000 shares subject to the award; filing shows $0.00 per share in the reported line.
• Shares owned after transaction: Not specified in the provided filing excerpt.
• Footnote: F1 — “Shares subject to the option vest in 48 equal monthly installments beginning on February 26, 2026.”
• No 10b5-1 plan, tax withholding, cashless exercise, or sale information indicated in the excerpt.

Context

• This is a time‑vested option/award that vests monthly over four years; it does not represent an immediate market purchase or sale and therefore is not a direct bullish or bearish trading signal by itself. Retail investors should treat grants as part of executive compensation and look for future exercises or sales for clearer insider market activity.